Communications Biology (May 2024)

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC

  • Thomas G. Hayhow,
  • Beth Williamson,
  • Mandy Lawson,
  • Natalie Cureton,
  • Erin L. Braybrooke,
  • Andrew Campbell,
  • Rodrigo J. Carbajo,
  • Azadeh Cheraghchi-Bashi,
  • Elisabetta Chiarparin,
  • Coura R. Diène,
  • Charlene Fallan,
  • David I. Fisher,
  • Frederick W. Goldberg,
  • Lorna Hopcroft,
  • Philip Hopcroft,
  • Anne Jackson,
  • Jason G. Kettle,
  • Teresa Klinowska,
  • Ulrike Künzel,
  • Gillian Lamont,
  • Hilary J. Lewis,
  • Gareth Maglennon,
  • Scott Martin,
  • Pablo Morentin Gutierrez,
  • Christopher J. Morrow,
  • Myria Nikolaou,
  • J. Willem M. Nissink,
  • Patrick O’Shea,
  • Radoslaw Polanski,
  • Markus Schade,
  • James S. Scott,
  • Aaron Smith,
  • Judith Weber,
  • Joanne Wilson,
  • Bin Yang,
  • Claire Crafter

DOI
https://doi.org/10.1038/s42003-024-06238-x
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Targeting the estrogen receptor alpha (ERα) pathway is validated in the clinic as an effective means to treat ER+ breast cancers. Here we present the development of a VHL-targeting and orally bioavailable proteolysis-targeting chimera (PROTAC) degrader of ERα. In vitro studies with this PROTAC demonstrate excellent ERα degradation and ER antagonism in ER+ breast cancer cell lines. However, upon dosing the compound in vivo we observe an in vitro-in vivo disconnect. ERα degradation is lower in vivo than expected based on the in vitro data. Investigation into potential causes for the reduced maximal degradation reveals that metabolic instability of the PROTAC linker generates metabolites that compete for binding to ERα with the full PROTAC, limiting degradation. This observation highlights the requirement for metabolically stable PROTACs to ensure maximal efficacy and thus optimisation of the linker should be a key consideration when designing PROTACs.